Drug intelligence / Profile preview

GB104

Development stage: Phase 1
Lead developer: GI Biome
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

GB104 is an orally administered investigational live biotherapeutic product composed of a lyophilized single bacterial strain, *Lactiplantibacillus plantarum* GB104, being developed by GI Biome and GI Longevity. It is being studied primarily in colorectal cancer and lower anterior resection syndrome after curative colectomy, where phase 1 clinical data showed favorable safety, tolerability, high compliance, and signals of improvement in bowel function. Preclinical work suggests GB104 has immunomodulatory and anti-tumor activity in syngeneic murine cancer models, while separate metabolic-disease studies indicate this strain can stimulate GLP-1 secretion, improve glucose control, limit weight gain, and reduce inflammatory macrophage polarization, supporting its classification as a microbiome-based therapeutic rather than a conventional small-molecule or biologic drug.

Other names: Lactiplantibacillus plantarum GB104

Beyond the preview

Go deeper on GB104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB104.

Explore the full profile